Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15659482 | 1.00 | CYP3A4 (0.34) | CYP3A4MAPTHPGDTOP2A | |
| SCHEMBL17627244 | 1.00 | CYP3A4 (0.34) | CYP3A4MAPTHPGDTOP2A | |
| SCHEMBL15659627 | 1.00 | CYP3A4 (0.34) | CYP3A4MAPTHPGDTOP2A | |
| SCHEMBL6825515 | 1.00 | CYP3A4 (0.34) | CYP3A4MAPTHPGDTOP2A | |
| SCHEMBL898414 | 1.00 | CYP3A4 (0.34) | CYP3A4MAPTHPGDTOP2A | |
| SCHEMBL23489728 | 0.90 | MAPT (0.33) | MAPTHPGDTOP2A | |
| SCHEMBL15661135 | 0.89 | CYP3A4 (0.32) | CYP3A4MAPTHPGD | |
| SCHEMBL15657817 | 0.89 | CYP3A4 (0.32) | CYP3A4MAPTHPGD | |
| SCHEMBL15660928 | 0.89 | CYP3A4 (0.32) | CYP3A4MAPTHPGD | |
| SCHEMBL17913474 | 0.87 | CYP3A4 (0.33) | CYP3A4TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20210170037-A1 | BRANCHED SUGAR ALCOHOL-BASED COMPOUNDS, AND COMPOSITIONS AND METHODS THEREOF | CELLMOSAIC INC (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2975024-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20140121175-A1 | ANTITUMOR AGENT | KINKI UNIVERSITY (JP) | 2014-05-01 | — | — | US | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| EP-0812825-B1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2004-02-11 | — | — | EP | disclosed |
| US-5952355-A | 1-ETHER-SUBSTITUTED PHENYL-3-INDOL-3-YL-2-PROPEN-1-ONE DERIVATIVES; ANTITUMOR AND -CARCINOGENIC AGENTS; IMMUNOSUPPRESSANTS; AUTOIMMUNE DISEASES; SIDE EFFECT REDUCTION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0812825-A1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CYP3A4 2585/4885MAPT 68/4885HPGD 4633/4885 |
| US-20210170037-A1 | BRANCHED SUGAR ALCOHOL-BASED COMPOUNDS, AND COMPOSITIONS AND METHODS THEREOF | SIGLEC7, CD44, SIGLEC9 | CYP3A4 2720/4885MAPT 545/4885HPGD 4414/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CYP3A4 2585/4885MAPT 68/4885HPGD 4633/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CYP3A4 2585/4885MAPT 68/4885HPGD 4633/4885 |
| US-20140121175-A1 | ANTITUMOR AGENT | UGCG, MAN1B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP3A4 4699/4885MAPT 4633/4885HPGD 3052/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CYP3A4 2585/4885MAPT 68/4885HPGD 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.